Kertes PJ, Galic IJ, Greve M, et al. - Researchers conducted this randomized clinical trial to compare the effectiveness of ranibizumab utilizing a treat-and-extend (T&E) regimen to monthly dosing in treatment-naive individuals with neovascular age-related macular degeneration (nAMD) after 24 months. The sample consisted of 580 individuals [mean (SD) age was 78.8 (7.8) years] with treatment-naive choroidal neovascularization secondary to AMD. Compared with the monthly dosing regimen, a lower mean number of injections was reported for T&E at month 24. Such results indicate that baseline vision change is not worse with a T&E vs a monthly ranibizumab regimen for nAMD through 24 months, achieving clinically significant improvements in BCVA despite fewer injections and visits.